IDEAYA, Gilead Plan More Collaboration on Trodelvy, IDE397 in Lung Cancer

 

• Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in MTAP-deletion NSCLC
• The potential first-in-class clinical combination of IDE397 and Trodelvy targets two mechanistically distinct and complementary nodes of MTAP-deletion in solid tumors
• MTAP-deletion prevalence in NSCLC is estimated to be approximately 15%

https://www.prnewswire.com/news-releases/ideaya-announces-further-gilead-sciences-clinical-study-collaboration-evaluating-combination-of-trodelvy-and-ide397-in-mtap-deletion-nsclc-302375663.html